BioSpace News Archive

Technavio has been monitoring the global bone distractors market since 2018 and the market is poised to grow by USD 71.94 million during 2019-2023, progressing at a CAGR of close to 6% during the forecast period.

Glaukos Corporation announced that its products will be included in various presentations at the 37th Congress of the European Society of Cataract and Refractive Surgeons, which begins Saturday, September 14, 2019 at the Paris Expo, Porte de Versailles in Paris, France.

Abbott (NYSE: ABT), the global leader in sensor-based glucose monitoring, announced today that it has received public reimbursement in Ontario and Quebec for its FreeStyle® Libre system, becoming the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

Qfix MRimage and Treat positioning products offer solutions that enable patients to benefit from MR, CT and treatment - all using the same device.

IRRAS AB, a commercial stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Vinny Podichetty VP, Clinical, Regulatory Affairs & Quality has resigned for personal reasons, and two key appointments to drive IRRAS’ continued growth.

Third Coast Therapeutics, a biotechnology company dedicated to developing orally active, small-molecule drugs, is pleased to announce its chief executive officer, Joseph Luminiello, was named a 2019 Notable Entrepreneur by Crain’s Chicago Business

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will provide Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, to a pediatric patient diagnosed with Niemann-Pick Disease Type C. The company received notice today of the FDA approval of the individual IND application from the treating physician

PanTheryx, a biotechnology company, today announced that it has appointed Dr. Mehmet C. Oz, MD, surgeon and talk show host “Dr. Oz” from The Dr. Oz Show, to the company’s board of directors.

Xstrahl, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is spotlighting its full range of superficial/orthovoltage treatments systems and radiation research platforms at ASTRO 2019.

MBP Solutions, the pioneering and world-leading provider of biological by-product outsourcing services (OMBP), today celebrates its 20th anniversary in business and revealed its new, updated corporate identity - developed to support the continuing growth of the business based on turning one industry’s by-product into another industry’s raw material.